Evidence map›Paper›PMID 40225385›Full record

ArticleKidney international reports2025

A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment.

Yan Ouyang, Yafei Zhao, Miantang Chen, Junru Li, Xinyi Zhu, Qing Zhao, Hong Ren, Jiali Wei, Nan Chen, Xiaoxia Pan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Renal failure · 2026
    Trial
  3. Review
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yan OuyangDepartment of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
Yafei ZhaoDepartment of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
Miantang ChenDepartment of Nephrology, Ruijin-Hainan Hospital, Shanghai Jiao Tong University, School of Medicine (Hainan Boao Research Hospital), Hainan, China.
Junru LiDepartment of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
Xinyi ZhuDepartment of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
Qing ZhaoDepartment of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
Hong RenDepartment of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
Jiali WeiDepartment of Nephrology, Hainan Affiliated Hospital of Hainan Medical College, Haikou, China.
Nan ChenDepartment of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
Xiaoxia PanDepartment of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
Jingyuan XieDepartment of Nephrology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

IgA nephropathynefeconsevere renal impairmenttreatment

Identifiers

PMID40225385
PMCPMC11993195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.